F-star Therapeutics to Announce First Quarter Results and Corporate Update Call on May 17, 2021

Rhea-AI Summary

F-star Therapeutics (NASDAQ: FSTX) announced an upcoming investor conference call scheduled for May 17, 2021, at 9:00 a.m. EST. The call will cover the financial results for the quarter ending March 31, 2021, along with a corporate update. Participants can join via a live webcast on the company’s website or by phone using provided international numbers. The conference call will also be available for replay for 90 days. F-star focuses on developing tetravalent bispecific antibodies aimed at improving cancer treatment outcomes.

Positive

• Hosting an investor conference to discuss financial results and corporate updates.
• Focus on developing innovative immunotherapies for cancer treatment.

Negative

• None.

CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., May 10, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer, announced today that it will host an investor conference call and webcast on Monday, May 17, 2021 at 9:00 a.m. EST to discuss financial results for the quarter ending March 31, 2021 and provide a corporate update.

To access the call, participants may join via a live webcast on the Investors and News section of the F-star Therapeutics website, under Events and Presentations. To join by phone, participants may dial 1-833-471-0868 in the US/Canada or 1-914-987-7751 for International calls or 0800 0288438 or 0203 1070289 for the United Kingdom, at least 10 minutes prior to the start of the call.

A replay of the conference call will be available for 90 days from the call and may be accessed in the Investors & News/Events and Presentations section on the F-star Therapeutics website.

About F-star Therapeutics, Inc.

F-star is a clinical-stage biopharmaceutical company developing tetravalent bispecific antibodies for a paradigm-shift in cancer therapy. By developing medicines that seek to block tumor immune evasion, the Company’s goal is to offer patients greater and more durable benefits than current immuno-oncology treatments. Through its proprietary tetravalent, bispecific natural antibody (mAb²™) format, F-star’s mission is to generate highly differentiated best-in-class drug candidates with monoclonal antibody-like manufacturability. For more information visit https://www.f-star.com/ and follow us on LinkedIn and Twitter.

For further information, please contact:

For investor inquiries
Lindsey Trickett
VP Investor Relations & Communications
+1 240 543 7970
lindsey.trickett@f-star.com

For media inquiries
Helen Shik
Shik Communications LLC
617-510-4373
Shik.Helen10@gmail.com

FAQ

What is F-star Therapeutics planning to discuss on May 17, 2021?

F-star Therapeutics will discuss financial results for the quarter ending March 31, 2021, and provide a corporate update during their conference call.

How can I access the F-star Therapeutics investor conference call?

You can access the conference call via a live webcast on F-star Therapeutics' website or by dialing specific phone numbers provided in their press release.

What is the focus of F-star Therapeutics?

F-star Therapeutics is dedicated to developing next-generation immunotherapies, specifically tetravalent bispecific antibodies, to enhance cancer treatment.